中国P站

Circulating biomarkers; Liquid biopsy; ctDNA; CTCs; Soft tissue sarcoma; Bone tumors; Exosomes; Orthopedic oncology; Tumor profiling; Non-invasive diagnostics

Introduction

Bone and soft tissue tumors encompass a heterogeneous group of neoplasms that pose significant challenges in diagnosis, prognosis, and treatment monitoring. Conventional diagnostic approaches including imaging and tissue biopsy while effective, are often invasive and limited in their ability to provide a comprehensive understanding of tumor heterogeneity, evolution, and systemic behaviour [1]. In recent years, the concept of liquid biopsy has emerged as a non-invasive, repeatable, and dynamic method to assess circulating biomarkers reflective of tumor characteristics. Liquid biopsy allows for the collection and analysis of biological materials shed by tumors into the bloodstream or other fluids, offering significant potential in orthopedic oncology for earlier detection, real-time monitoring, and personalized treatment strategies [2].

Description

The foundation of liquid biopsy lies in its ability to detect and analyze various circulating biomarkers. These include ctDNA, CTCs, miRNAs, proteins, and extracellular vesicles such as exosomes. Each of these components provides distinct insights into tumor biology:

Circulating Tumor DNA (ctDNA): Fragments of DNA released into the bloodstream by apoptotic and necrotic tumor cells. ctDNA carries tumor-specific mutations and epigenetic alterations, enabling molecular profiling of tumors. Its presence and quantity often correlate with tumor burden and disease progression [3].

Circulating Tumor Cells (CTCs): Viable cancer cells that detach from primary or metastatic tumors and circulate in the peripheral blood. CTC enumeration and characterization can offer prognostic information and insights into mechanisms of metastasis and resistance.

MicroRNAs (miRNAs): Small non-coding RNA molecules that regulate gene expression. Tumor-specific miRNA signatures can serve as biomarkers for diagnosis, prognosis, and therapeutic response.

Exosomes: Nano-sized extracellular vesicles containing DNA, RNA, and proteins. Exosomes facilitate intercellular communication and can reflect the genetic and proteomic landscape of tumors [4].

The relevance of these biomarkers in orthopedic oncology is increasingly evident. Sarcomas, both of bone and soft tissue origin, are rare and biologically diverse malignancies, with unpredictable clinical behavior. Liquid biopsy offers the opportunity to monitor these tumors non-invasively, track therapeutic responses, and detect minimal residual disease or recurrence before radiologic evidence appears [5].

Discussion

The application of circulating biomarkers in bone and soft tissue tumors has demonstrated considerable promise in multiple aspects of clinical care:

Early Detection and Diagnosis: In cancers like osteosarcoma and Ewing sarcoma, early diagnosis is crucial for effective treatment. ctDNA and miRNA signatures can serve as potential biomarkers for distinguishing malignant from benign lesions or for early detection in high-risk populations.

Tumor Heterogeneity and Clonal Evolution: Liquid biopsy provides a broader view of tumor heterogeneity than a single tissue biopsy, capturing subclonal mutations and dynamic genetic changes. This is particularly relevant in high-grade sarcomas, where genetic evolution under treatment pressure can lead to resistance [6].

Monitoring Treatment Response: Fluctuations in ctDNA levels can reflect tumor response to chemotherapy, radiotherapy, or targeted therapy, often preceding changes seen on imaging. Similarly, CTC counts and phenotypic changes can indicate therapeutic efficacy or failure.

Detection of Minimal Residual Disease (MRD) and Recurrence: After surgical resection or systemic therapy, persistent or rising ctDNA levels may indicate residual disease or impending recurrence, allowing for timely intervention [7].

Prognostication: Several studies have shown that the presence of specific mutations or high levels of circulating biomarkers correlates with poor prognosis. For example, elevated CTC counts in metastatic sarcoma have been associated with decreased overall survival [8].

Despite these advantages, challenges remain in the clinical implementation of liquid biopsy in orthopedic oncology:

Technical Sensitivity and Specificity: Detecting low levels of ctDNA or rare CTCs in peripheral blood requires highly sensitive techniques. False negatives may occur in low-burden disease or in tumors that do not shed detectable biomarkers [9].

Standardization and Validation: There is currently no universally accepted protocol for sample collection, processing, and analysis. Variability in methods can impact reproducibility and clinical interpretation [10].

Tumor Type-Specific Considerations: The biological behavior and shedding characteristics of bone versus soft tissue tumors vary widely. Not all sarcomas release measurable ctDNA or CTCs, necessitating tailored biomarker panels for each tumor subtype.

Cost and Accessibility: High costs and limited availability of sophisticated molecular platforms can restrict widespread use, particularly in resource-limited settings.

Nevertheless, the trajectory of research and development in this field is optimistic. Ongoing clinical trials are evaluating the utility of ctDNA for monitoring osteosarcoma, the prognostic value of CTCs in soft tissue sarcoma, and the role of exosomal miRNAs as therapeutic targets. Integration of artificial intelligence and machine learning in biomarker analysis is expected to enhance predictive modeling and individualized patient care. Importantly, the use of liquid biopsy does not eliminate the need for traditional diagnostics but complements them. It enables orthopedic oncologists to adopt a more comprehensive, dynamic, and less invasive approach to cancer care one that aligns with the principles of precision medicine.

Conclusion

Circulating biomarkers accessed through liquid biopsy represent a transformative advancement in the diagnosis and management of bone and soft tissue tumors. By enabling real-time, non-invasive tumor monitoring, liquid biopsy offers significant advantages over conventional methods, particularly in tracking tumor dynamics, detecting recurrence, and guiding personalized therapy. While technical and logistical challenges remain, the clinical potential of this approach is vast and rapidly expanding. As research progresses and methodologies become standardized, liquid biopsy is poised to become an integral component of musculoskeletal oncology, ushering in a new era of precision and patient-centered care.

References

1. Ewepu G (2021) . Vanguard Newspaper. 2nd January.

2. Akpotayire SI, Miikue-Yobe TFB, Kalagbor IA, Okpabi DA, Nwoha N, et al. (2018) . AJSR 6: 216-221.

   , Crossref

3. Orobator PO, Akin-Obaroakpo TM, Orowa R (2020) . J res for wildl environ 12: 24-33.

   ,

4. Adeleke B, Robertson-Anderson D, Moodley G, Taylor S (2020) . Rev Fish Sci Aquac 9.

   , ,

5. Anetekhai AM (2010) 9: 73-76.

6. Atanda A (2007) . In: Bondad-Reantaso MG, editor. Assessment of freshwater fish seed resources for sustainable aquaculture. FAO Fisheries Technical Paper No. 501. Rome: FAO 361-380.

7. Oyeleye OO, Omitogun OG (2007) . IJA 22: 11-16.

8. Adewumi AA, Olaleye VF (2017) . J Environ Sci Technol 8: 1-5.

   , , Crossref

9. Ogugua NM, Eyo JE (2007) . Res J Biol Sci 3: 23-39.

   ,

10. Akinrotimi OA, Gabriel UU, Owhonda NK, Onunkwo DN, Opara JY, et al. (2007a) . Agric J 2: 606-612.